What’s Behind The Jump In ImmunityBio Stock?

All NewsFebruary 18, 2026

ImmunityBio shares are higher on Wednesday after the European Commission authorized one of its treatments for bladder cancer carcinoma.

Importance Rank:

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent